Geoffrey Symonds

Prof. Geoffrey Symonds


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2015 in Viruses
Verified
Journal Article
Open access
PDF file
GHGero Hütter
Gero Hütter
JBJosef Bodor
Josef Bodor
SLScott Ledger
Scott Ledger
MBMaureen Boyd
Maureen Boyd
MMMichelle Millington
Michelle Millington
GSGeoffrey Symonds
Geoffrey Symonds
Allogeneic transplantation with CCR5-delta 32 (CCR5-d32) homozygous stem cells in an HIV infected individual in 2008, led to a sustained virus control and probably eradication of HIV. Since then there has been a high degree of interest to translate this approach to a wider population. There are two cellular ways to do this. The first one is to use a CCR5 negative cell source e.g., hematopoietic stem cells (HSC) to copy the initial finding. However, a recent case of a second allogeneic transplantation with CCR5-d32 homozygous stem cells suffered from viral escape of CXCR4 quasi-species. The second way is to knock down CCR5 expression by gene therapy. Currently, there are five promising techniques, three of which are presently being tested clinically. These techniques include zinc finger nucleases (ZFN), clustered regularly interspaced palindromic repeats/CRISPR-associated protein 9 nuclease (CRISPR/Cas9), transcription activator-like effectors nuclease (TALEN), short hairpin RNA (shRNA), and a ribozyme. While there are multiple gene therapy strategies being tested, in this review we reflect on our current knowledge of inhibition of CCR5 specifically and whether this approach allows for consequent viral escape.

1 January 2014 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
OWOrit Wolstein
Orit Wolstein
MBMaureen Boyd
Maureen Boyd
MMMichelle Millington
Michelle Millington
HIHelen Impey
Helen Impey
JBJoshua Boyer
Joshua Boyer
GSGeoffrey Symonds
Geoffrey Symonds
An international, open-access journal publishing top-quality, novel methods and technology development, as well as significant improvements to established techniques in basic, translational, and clinical cell and gene therapy.

30 December 2013 in Viruses
Verified
Journal Article
Open access
PDF file
BBBryan P. Burke
Bryan P. Burke
MBMaureen P. Boyd
Maureen P. Boyd
HIHelen Impey
Helen Impey
LBLouis R. Breton
Louis R. Breton
JBJeffrey S. Bartlett
Jeffrey S. Bartlett
GHGero Hütter
Gero Hütter
Human immunodeficiency virus type 1 (HIV-1) infection of target cells requires CD4 and a co-receptor, predominantly the chemokine receptor CCR5. CCR5-delta32 homozygosity results in a truncated protein providing natural protection against HIV infection—this without detrimental effects to the host—and transplantation of CCR5-delta32 stem cells in a patient with HIV (“Berlin patient”) achieved viral eradication. As a more feasible approach gene-modification strategies are being developed to engineer cellular resistance to HIV using autologous cells. We have developed a dual therapeutic anti-HIV lentiviral vector (LVsh5/C46) that down-regulates CCR5 and inhibits HIV-1 fusion via cell surface expression of the gp41-derived peptide, C46. This construct, effective against multiple strains of both R5- and X4-tropic HIV-1, is being tested in Phase I/II trials by engineering HIV-resistant hematopoietic cells.

25 August 2010 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
GSGeoffrey Symonds
Geoffrey Symonds
HJHelen A. Johnstone
Helen A. Johnstone
MMMichelle L. Millington
Michelle L. Millington
MBMaureen P. Boyd
Maureen P. Boyd
BBBryan P. Burke
Bryan P. Burke
LBLouis R. Breton
Louis R. Breton

1 February 2018 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
SLScott Ledger
Scott Ledger
AHAnnett Howe
Annett Howe
Stuart TurvilleStuart Turville
Stuart Turville
AAAnupriya Aggarwal
Anupriya Aggarwal
BSBorislav Savkovic
Borislav Savkovic
GSGeoffrey Symonds
Geoffrey Symonds

7 December 2016 in Genes
Verified
Journal Article
Open access
PDF file
VKVera Klemm
Vera Klemm
JMJye Mitchell
Jye Mitchell
CCChristina Cortez-Jugo
Christina Cortez-Jugo
Francesca CavalieriFrancesca Cavalieri
Francesca Cavalieri
GSGeoffrey Symonds
Geoffrey Symonds
CAChantelle Ahlenstiel
Chantelle Ahlenstiel
HIV-1 infection has been transformed by combined anti-retroviral therapy (ART), changing a universally fatal infection into a controllable infection. However, major obstacles for an HIV-1 cure exist. The HIV latent reservoir, which exists in resting CD4+ T cells, is not impacted by ART, and can reactivate when ART is interrupted or ceased. Additionally, multi-drug resistance can arise. One alternate approach to conventional HIV-1 drug treatment that is being explored involves gene therapies utilizing RNA-directed gene regulation. Commonly known as RNA interference (RNAi), short interfering RNA (siRNA) induce gene silencing in conserved biological pathways, which require a high degree of sequence specificity. This review will provide an overview of the silencing pathways, the current RNAi technologies being developed for HIV-1 gene therapy, current clinical trials, and the challenges faced in progressing these treatments into clinical trials.